The 25 references in paper Г. Березовская А., О. Смирнова А., Н. Петрищев Н., Л. Папаян П., М. Карпенко А., О. Головина Г., Н. Хромов-Борисов Н., Г. Березовская А., О. Смирнова А., Н. Петрищев Н., Л. Папаян П., М. Карпенко А., О. Головина Г., Н. Хромов-Борисов Н. (2015) “ТЕСТ ГЕНЕРАЦИИ ТРОМБИНА В ОЦЕНКЕ ДЕЙСТВИЯ АНТИАГРЕГАНТОВ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА” / spz:neicon:aterotromboz:y:2015:i:1:p:40-51

1
Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol, 2006, 48: 2440–7.
(check this in PDF content)
2
Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol,2009, 104: 227–33.
(check this in PDF content)
3
Can MM, Tanboga IH, Turkyilmaz E, Karabay CY, Akgun T, Koca F et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparision of the PFA100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res, 2010, 125: e132–7.
(check this in PDF content)
4
Hemker HC, Wielders S, Kessels H, BОguin S. Continuous registration of thrombin generation in plasma. Its use for the derermination of the thrombin potential. Thromb Haemost,1993, 70: 617–24.
(check this in PDF content)
5
Al Dieri R, Alban S, BОguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost,2004, 2: 1395–401.
(check this in PDF content)
6
Al Dieri R, Alban S, BОguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost, 2006, 4: 83—9.
(check this in PDF content)
7
Gerotziafas GТ, Petropoulou AD, Verdy E, Samama MM, Elalamy I et al. Effect of the anti-factor Xa and anti-factor Ha activities of low-molecular weight heparins upon the phases of thrombin generation. J Thromb Haemost, 2007, 5: 955–62.
(check this in PDF content)
8
Stief T.W. Inhibition of thrombin generation in recalcified plasma. Blood Coagul Fibrinolysis, 2007, 18: 751–60.
(check this in PDF content)
9
Altman R, Scazziota A, Herrera L, GonzЗlez C. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin К antagonist therapy. J Thromb Haemost,2007, 5: 1552—69.
(check this in PDF content)
10
Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb,2003, 33: 43–51.
(check this in PDF content)
11
Gatt A, van Veen JJ, Bowyer A, Cooper PC, Kitchen S, Markus M. Significant variation in thrombin generation potential in «adequately» anticoagulated patients. J Thromb Haemost, 2007, 5(Suppl. S2): P-M-097.
(check this in PDF content)
12
Altman R, Scazziota A, Santoro S, GonzЗlez C. Abciximab does not inhibit the increase of thrombin generation produced in plateletrich plasma in vitro by sodium arachidonate or tissue factor. Clin Appl Thromb Hemost, 2005, 11: 271–77.
(check this in PDF content)
13
Altman R, Scazziota A, de Lourdes Herrera M, Gonzalez C. Recombinant factor Vila reverses the inhibitory effect of aspirin or as pirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost, 2006, 4: 2022–27.
(check this in PDF content)
14
Матвиенко О.Ю., Наместников Ю.А. , Хаит Е.А., Головина О.Г., Папаян Л.П., Герасименко Д.В и соавт. Гиперкоагуляционный синдром при ишемическом инсульте. Клин геронтол,2011, 9–10: 34–38.
(check this in PDF content)
15
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb,2003, 33: 4–15.
(check this in PDF content)
16
Гайдышев И.П. Проект Attestat. Программное обеспечение анализа данных AtteStat. 2002–2014. http:// ilizarov.center/?page_id=82.
(check this in PDF content)
17
Hammer O, Harper DAT, Ryan PD. PAST: Paleontological statistics software package for education and data analysis // Palaeontologia Electronica 2001; 4: 9pp. http:// palaeoelectronica.org/2001_1/past/issue1_01.htm.
(check this in PDF content)
18
ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 2013; 1–17. http:// www.icmje.org/recommendations/
(check this in PDF content)
19
Kraemer HC, Frank E, J Kupfer D. How to assess the clinical impact of treatments on patients, rather than the statistical impact of treatments on measures. Int J Methods Psychiatr Res,2011, 20: 63–72.
(check this in PDF content)
20
Ланг Т.А., Сесик М. Как описывать статистику в медицине. Руководство для авторов, редакторов и рецензентов. М.: Практическая медицина, 2011.
(check this in PDF content)
21
Тишков А.В., Хромов-Борисов Н.Н., Комашня А.В., Марченкова Ф.Ю., Семенова Е.М., Эюбова Н.Т. и соавт. Статистический анализ таблиц в диагностических исследованиях. СПб.: Изд-во СПбГМУ, 2013.
(check this in PDF content)
22
Muller O, Bartunek J, Hamilos M, Berza CT, Mangiacapra F, Ntalianis A et al. von Willebrand factor inhibition improves endothelial function in patients with stable angina. J Cardiovasc Transl Res, 2013, 6: 364–70.
(check this in PDF content)
23
Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll. Cardiol, 2013, 61: 2115–29.
(check this in PDF content)
24
Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest,1993, 92: 2003–12.
(check this in PDF content)
25
Siller-Matula JM, Bayer G, Bergmeister H, Quehenberger P, Petxelbauer P, Friedl P et al. An experimental model to study isolated effects of thrombin in vivo. Thromb Res, 2010, 126: 454–61.
(check this in PDF content)